PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
Site Search
Showing 11 - 20 of 21 results
News
|
|
1 min read
News
|
|
2 min read
News
|
|
2 min read
News
|
|
1 min read
News
|
|
1 min read
News
|
|
3 min read
Press Release
|
|
5 min read
Press Release
|
|
3 min read
Expanded Research Lab to Apply Latest Scientific Advances -- Including Stem Cell Research and Gene Editing -- to Accelerate New Treatments for CF
Press Release
|
|
3 min read
Press Release
|
|
2 min read